Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

医学 外科 危险系数 置信区间 胃肠病学 内科学
作者
Alexander E. Perl,Richard A. Larson,Nikolai A. Podoltsev,Stephen A. Strickland,Eunice S. Wang,Ehab Atallah,Gary J. Schiller,Giovanni Martinelli,Andreas Neubauer,Jorge Sierra,Pau Montesinos,Christian Récher,Sung‐Soo Yoon,Naoko Hosono,Masahiro Onozawa,Shigeru Chiba,Hee‐Je Kim,Nahla Hasabou,Qiaoyang Lu,Ramón V. Tiu,Mark J. Levis
出处
期刊:Blood [Elsevier BV]
卷期号:139 (23): 3366-3375 被引量:92
标识
DOI:10.1182/blood.2021011583
摘要

Abstract The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib in these patients with AML. At the time of this analysis, the median survival follow-up was 37.1 months, with deaths in 203 of 247 and 97 of 124 patients in the gilteritinib and SC arms, respectively; 16 gilteritinib-treated patients remained on treatment. The median overall survival for the gilteritinib and SC arms was 9.3 and 5.6 months, respectively (hazard ratio, 0.665; 95% confidence interval [CI], 0.518, 0.853; two-sided P = .0013); 2-year estimated survival rates were 20.6% (95% CI, 15.8, 26.0) and 14.2% (95% CI, 8.3, 21.6). The gilteritinib-arm 2-year cumulative incidence of relapse after composite complete remission was 75.7%, with few relapses occurring after 18 months. Overall, 49 of 247 patients in the gilteritinib arm and 14 of 124 patients in the SC arm were alive for ≥2 years. Twenty-six gilteritinib-treated patients remained alive for ≥2 years without relapse; 18 of these patients underwent transplantation (hematopoietic stem cell transplantation [HSCT]) and 16 restarted gilteritinib as post-HSCT maintenance therapy. The most common adverse events of interest during years 1 and 2 of gilteritinib therapy were increased liver transaminase levels; adverse event incidence decreased in year 2. Thus, continued and post-HSCT gilteritinib maintenance treatment sustained remission with a stable safety profile. These findings confirm that prolonged gilteritinib therapy is safe and is associated with superior survival vs SC. This trial was registered at www.clinicaltrials.gov as #NCT02421939.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
3秒前
笨笨青筠完成签到 ,获得积分10
6秒前
mengmenglv完成签到 ,获得积分0
6秒前
Tonald Yang完成签到 ,获得积分20
9秒前
10秒前
落后的怀梦完成签到 ,获得积分10
11秒前
陈坤完成签到,获得积分10
13秒前
量子星尘发布了新的文献求助10
15秒前
斯文败类应助zgx采纳,获得10
16秒前
默默完成签到 ,获得积分10
16秒前
KY Mr.WANG完成签到,获得积分10
16秒前
30秒前
guoxingliu完成签到,获得积分10
34秒前
42秒前
阳佟水蓉完成签到,获得积分10
43秒前
gdgd完成签到,获得积分10
46秒前
量子星尘发布了新的文献求助10
48秒前
叮叮当当完成签到,获得积分10
50秒前
53秒前
53秒前
电致阿光完成签到,获得积分10
54秒前
ccc完成签到 ,获得积分10
56秒前
57秒前
zgx发布了新的文献求助10
59秒前
i2stay完成签到,获得积分10
59秒前
馒头完成签到,获得积分10
1分钟前
MS903完成签到,获得积分10
1分钟前
CJW完成签到 ,获得积分10
1分钟前
韧迹完成签到 ,获得积分0
1分钟前
mmd完成签到 ,获得积分10
1分钟前
七一安完成签到 ,获得积分10
1分钟前
浪麻麻完成签到 ,获得积分10
1分钟前
包容的剑完成签到 ,获得积分10
1分钟前
等待的大炮完成签到,获得积分10
1分钟前
注水萝卜完成签到 ,获得积分10
1分钟前
Chem34完成签到,获得积分10
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022